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ABSTRACT
Background: Hypermetabolism and hyposomatotropism related to severe burns lead to 
impaired wound healing. Growth hormone (GH) boosts wound healing notably following 
stimulation of the production of insulin‑like growth factor‑1 (IGF1), a mitogen factor 
for keratinocytes. Gamma‑hydroxybutyrate (GHB) stimulates endogenous GH secretion.
Aim: To assess effects of GHB sedation on keratinocytes proliferation  (based on 
immunohistochemical techniques).
Design: Monocentric, prospective, controlled trial.
Materials and Methods: Patients (aging 18‑65 years, burn surface area >30%, expected 
to be sedated for at least one month) were alternately allocated, at the 5th  day 
following injury, in three groups according to the intravenous GHB dose administered 
for 21 days: Evening bolus of 50 mg/kg (Group B), continuous infusion at the rate of 
10 mg/kg/h (Group C), or absence of GHB (Group P). They all received local standard cares. 
Immunohistochemistry (Ki67/MIB‑1, Ulex europaeus agglutinin‑1 and Mac 387 antibodies) 
was performed at D21 on adjacent unburned skin sample for assessing any keratinocyte 
activation. Serum IGF1 levels were measured at initiation and completion of the protocol.
Statistical Analysis: Categorical variables were compared with Chi‑square test. Comparisons 
of medians were made using Kruskal‑Wallis test. Post hoc analyses were performed using 
Mann‑Whitney test with Bonferroni correction for multiple comparisons. A P < 0.05 was 
considered to be statistically significant.
Results: A total of 14 patients completed the study (Group B: n = 5, Group C: n = 5, 
Group P: n = 4). Continuous administration of GHB was associated with a significant 
higher Ki67 immunolabeling at D21 (P = 0.049) and with a significant higher increase in 
the IGF1 concentrations at D21 (P = 0.024). No adverse effects were disclosed.
Conclusions: Our preliminary data support a positive effect of GHB on keratinocyte 
proliferation and are encouraging enough to warrant large prospective studies.
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INTRODUCTION
Severe burn injury is associated to a hypermetabolic 
response, mediated by elevated catecholamines, 
corticosteroids, and proinflammatory cytokines. In 
addition, resistance to or suppression of circulating 
anabolic hormones is operative. Particularly, the growth 
hormone (GH)/insulin‑like growth factor 1 (IGF1) axis 
is affected. This may lead to impaired wound healing. 
Pharmacological strategy aiming to modulate this severe 
and prolonged hypermetabolic and hypercatabolic 
response particularly includes recombinant human 
growth hormone (rhGH). Unlike general intensive care 
population,[1] no adverse impact on mortality was observed 
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in burn patients. Beneficial effects of rhGH on metabolic 
status and wound healing were demonstrated.[2] However, 
rhGH effects are not higher than oxandrolone (an 
alternative anabolic hormone),[3] while disclosing adverse 
hyperglycemia.[4] Unfortunately, drug costs limit its 
administration. This treatment is currently indicated 
only in severe burn of children,[5] for whom proved GH 
deficiency is associated with growth impair.[5]
Gamma‑hydroxybutyrate (GHB) is a hypnotic 
drug inducing limited respiratory or hemodynamic 
depression.[6] Intravenous GHB is still used in clinical 
settings as an adjunct to anesthesia of hemodynamically 
instable patients[7] or sedation of intensive care patients.[8] 
Furthermore, GHB may have stimulatory effect on GH 
release.[9] Mechanism of this somatotropic action is not 
yet clearly understood: It could be related to its slow 
wave sleep induction. Indeed, there is a consistent 
relationship between the appearance of delta waves on 
the electroencephalogram (EEG) and GH secretion.[10]
To the best of our knowledge, only a single study 
has investigated the benefit of GHB administration 
on wound healing in burn subjects: It was an animal 
assay in a rat model.[11] As GHB can be considered 
as a GH‑releasing agent, we hypothesized that GHB 
administered during the early hypermetabolic phase 
would stimulate proliferation of epidermal cells, 
through stimulation of the liver production of IGF1. 
The aim of the present preliminary human study was 
therefore to assess the effect of 21 days ‑ GHB sedation 
on keratinocytes stimulation and proliferation, based on 
immunohistochemical techniques. Our secondary aim 
was to assess its effects on IGF1 blood concentrations.
MATERIALS AND METHODS
Subjects
The study protocol was approved by the local Ethics 
Committee of our Military Teaching Hospital and by 
the 8th Ethical Research Committee of the Ile de France 
Region (reference SC 10 06 60). The study was registered 
in the EudraCT database under reference 2010‑A00475‑34. 
Informed written consent was obtained from the 
family members of the patients prior to enrolment. The 
study was conducted from May 2010 to January 2011 
in a 16‑bed burn unit. Inclusion criteria were: Total 
burn surface area (TBSA) greater than 30%, expected 
sedation for at least one month, age between 18 and 
65 years (delayed wound healing is observed after 
65 years). Pregnancy, active cancer disease, pituitary or 
suprarenal insufficiency, diabetes mellitus, and chronic 
renal or liver failure were considered exclusion criteria.
Study protocol
Our study was a monocentric, prospective, controlled trial.
All patients benefited from local standard monitoring 
and care procedures. Sedation was based on midazolam; 
analgesia was based on paracetamol and morphine. 
Enteral feeding was prescribed to obtain intakes of 
35 kcal/kg/d and 0.4 g of nitrogen/kg/d. Diet was 
supplemented with ornithine α‑ketoglutarate, a glutamine 
and arginine precursor, administered twice daily as 
an enteral bolus of 10 g (Cetornan®, Chiesi, France). 
Patients also received daily intravenous micronutrient 
supplementation: 1 g acid ascorbic, 100μg selenium, 
5mg calcium folinate, a multivitamin preparation 
(Cernevit®, Baxter, USA), and a multi‑trace‑element 
preparation (Tracutil®, B Braun Medical, Germany). 
Intravenous insulin was administered to maintain blood 
glucose level between 0.8 and 1.4 g/l (euglycemia). 
Dextrose 5% or 2.5% (D5% or D2.5%) infusion rates were 
adjusted according to natremia. Hypokaliemia was treated 
using potassium chloride (KCl) supplementation. Deep 
burns benefited from early excision and grafting. Dressings 
were changed every third days under general anesthesia.
After inclusion, patients were assigned to receive 
intravenous GHB as 50 mg/kg bolus at 21 pm (group B) 
or as a continuous infusion (group C) at the rate of 
10 mg/kg/h for 21 days, starting at the fifth day after 
injury (day 0 = D0). Patients assigned in group P did 
not receive GHB: They were considered as a negative 
control group. Allocation was based on admission timing: 
Patients were consecutively assigned in group C first, 
then in group B, and finally in group P. This pattern was 
repeated each 3 patients. Only intensivists and nurses 
were aware of this alternate allocation. Patients, surgeons, 
dermatopathologists, and clinical chemists were blinded 
to the group allocation.
There was no sample size calculation as it was a preliminary 
study with no relevant previous data. Number of 
admissions during the study period determined the 
sample size.
Evaluation of epithelial changes
Skin biopsy (4‑millimeter punch) was performed on 
day 21 (D21) of the protocol in apparently healthy 
skin close to an unhealed burn area. Histopathology 
assessment were blinded when submitted to an 
experienced dermatopathologist. Microscopical 
sections (6‑μm thick) were cut from the formalin‑fixed 
paraffin‑embedded punch biopsies. The sections were 
used for immunohistochemical assessments using a 
panel of antibodies (Ki67/MIB‑1, 1:100, Dako®; UEA‑1, 
1:2000, Sigma® and Mac387, 1:200, Dako®) and the 
avidin‑biotin peroxidase method. After a 1‑h incubation 
time with any of the primary antibodies, the slides were 
washed in Tris‑buffered saline (TBS) and incubated 
for 30 min with the secondary antibody (biotinylated 
swine antirabbit, 1:300, Dakopatts®). Slides were rinsed 
in TBS and covered by the EnVision (Dakopatts®, 
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Glostrup, Denmark) polymer‑based revelation system. 
After TBS washings, Fast Red (Dakopatts®) was used 
as chromogen substrate. The last steps consisted 
of counterstaining with Mayer hemalum before 
mounting. Negative immunohistochemical controls 
were performed by omitting or substituting the 
primary and the secondary antibodies of the laboratory 
procedure.
Ki67 antigen is a nuclear protein expressed in all 
proliferating cells. Ki67/MIB‑1 monoclonal antibody 
reveals the germinative compartment formed by all 
cells engaged in the cell cycle of proliferation. Mac 387 
monoclonal antibody specifically identifies L1‑protein. 
The L1‑protein, corresponding to calprotectin, consists of 
three calcium noncovalently bound polypeptide chains. 
It is expressed in reactive epidermis but also in mucosal 
epithelium, neutrophils, monocytes, and some reactive 
macrophages. Ulex europaeus agglutinin‑1 (UEA‑1) 
reacts with fucose moieties present on cell‑associated 
glycoproteins. It typically identifies reactive keratinocytes 
and endothelial cells.
The total number of Ki67+ keratinocyte was counted 
per mm length in 3 relevant contiguous sectors in each 
section before expressing these three counts as a mean 
number per biopsy specimen. The immunolabeling using 
UEA‑1 and Mac 387 was assessed semi‑quantitatively 
only in the epidermis in a 5‑grade scale according to: 
0 (absence), 1 (<1/3 epidermal thickness), 2 (>1/3 <2/3 
epidermal thickness), 3 (>2/3 epidermal thickness with 
skipped areas), and 4 (full thickness).
Hormonal assessments
A blood sample, collected through a central venous 
line placed for clinical use, was obtained at 7 am of D0 
and D21 for the measurement of IGF1. IGF1 levels were 
measured at that time of the morning for practical reason, 
as it is not release in a pulsatile way.
Blood was drawn into a serum gel tube (Vacutainer SST II 
Advance®, BD Diagnostics, USA), kept on melting ice, and 
quickly centrifuged (3500 rpm, 15 min, 4°C). Aliquots of 
the supernatant were finally stored at‑80°C. Measurement 
of IGF1 concentrations was made within 3 months 
after the end of the protocol. Levels were measured 
using a commercially available immuno‑luminometric 
assay (Liaison®, DiaSorin, Stillwater, MN, USA). Lower 
limit of sensitivity for IGF1 assays was 20 ng/ml.
Data analysis
The primary endpoint was the keratinocytes 
proliferation rate at D21, evaluated via the Ki67 
immunolabeling. UEA‑1 and Mac 387 labeling were 
also assessed in this aim. For each patient, results of 
the immunolabeling were considered as a mean of 
three sectors analyzed. The second endpoint was IGF1 
concentrations. For each patient, these results were 
analyzed regarding the difference between values at 
D21 and D0 (delta IGF1).
Statistical analysis
Statistical analysis was performed using Stata 
11.2 (StataCorp. 2009, College Station, TX, USA). Data 
are reported as ratio for proportions or as medians 
and ranges (min‑max) for continuous variables. 
Categorical variables were compared with Chi‑square 
test. Comparisons of medians were made using 
Kruskal‑Wallis test. Post hoc analyses were performed 
using Mann‑Whitney test with Bonferroni correction for 
multiple comparisons. A P < 0.05 was considered to be 
statistically significant.
RESULTS
A total of 14 patients were enrolled: They all completed 
the trial. Patients were all Caucasians. All cases were 
flame burns. Patient characteristics are presented in 
Table 1. Median age was 37 years old, median TBSA 
Table 1: Patients characteristics
Group B n=5 Group C n=5 Group P n=4 P value
Age (years) 38 (32-61) 33 (20-42) 45 (36-63) 0.11
Gender 2M/3F 5M 2M/2F 0.11
TBSA (%) 54 (27-61) 40 (35-65) 56 (39-72) 0.57
Deep BSA (%) 48 (14-55) 25 (23-55) 47 (17-50) 0.73
ABSI score 10 (9-12) 8 (6-9) 9 (6-14) 0.09
LOS (days) 52 (46-106) 47 (29-99) 71 (41-141) 0.45
Number of surgery 2 (1-4) 2 (1-3) 1 (0-3) 0.47
Delay between surgeries (days) 6.5 (6-18) 7.5 (4.6-17) 8.2 (5.5-11) 0.98
Excised surface area (%) 18 (6-41) 20.5 (3-39) 14 (0-36) 0.73
Proportion of healed burns (%) 66 (50-66) 70 (30-90) 52 (15-66) 0.35
PRBC (units) 13 (12-15) 11 (11-19) 12.5 (4-20) 0.63
Average Na (mmol/l) 142 (131-157) 140 (133-152)* 144 (135-156) 0,0001
Average K (mmol/l) 4 (3-4.7) 3.8 (2.9-4.7)* 4 (2.5-5.3) 0.0001
Insulin cumulated dose (UI) 170 (28-1224) 30 (0-316) 646 (114-2401) 0.2
Insulin (UI/kg/kcal/day) 0.2 (0-2.1) 0 (0-0.3) 0.9 (0.1-4.3) 0.14
TBSA: Total burn surface area, BSA: Burn surface area, M: Male, F: Female, LOS: Length of stay, PRBC: Packed red blood cells, Na: Blood sodium level, K: Blood 
potassium level. Data are presented as median (min-max) or proportions
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reached 52%, and ABSI score was 9. No statistical 
differences on epidemiologic data were observed between 
the three groups. However, there were more men in 
group C than in the two other groups. Group C patients 
tended to suffer from more severe burns.
Despite the lack of significant difference in length of 
hospital stay between groups, it tended to be shorter in 
group C. Surgical strategy was similar among groups 
during the study period. Proportion of healed burns at the 
end of the study period tended to be higher in group C, but 
difference between groups was not statistically significant.
There were no statistical differences between the 
three groups regarding the number of packed red 
blood cells (PRBC) units delivered to patients between 
admission and the end of the study period. Only one 
patient in group B received fresh frozen plasma (3 units) 
during this time. No patient received platelet transfusion 
during the study period.
Despite the lack of statistical significance, patients of 
group C tended to receive less intravenous insulin than 
patients of group B and P.
At D21, the mean Ki67+ keratinocytes number was 
significantly different between the three groups (P = 0.049), 
respectively 11 (9‑16), 23 (16‑38) and 4 (1‑20) in groups B, 
C and P [Figure 1]. After post‑hoc analysis, there was a 
trend toward higher values in group C when compared 
with group B (P = 0.07). No difference between groups 
was observed when looking to UEA‑1 or Mac 387 
immunolabeling in the epidermis [Table 2].
Delta IGF1 was statistically different between 
the three groups (P = 0.0264): results in groups B, 
C, and P were respectively 58.4 ng/ml (12.06‑100), 
107.41 ng/ml (51.1‑117.2), and 31.3 ng/ml (‑2.29‑40.9). 
Post‑hoc analysis showed a significant increase of 
IGF1 concentrations in group C when compared with 
group P (P = 0.042) [Figure 2].
No adverse events were disclosed under the present 
conditions of GHB administration. Patients of group B 
and C did not experience more severe hypernatremia 
or hypokaliemia than patients of group P [Table 1]. All 
included patients received similar amounts of free water 
infusion (D5% or D2.5%) and KCl.
DISCUSSION
Our preliminary data support a positive effect of 
GHB on keratinocyte proliferation. Such finding is in 
line with a previous report in a rat model.[11] Despite 
of the modest level of statistical significance in Ki67 
immunolabeling (most probably due to the small 
number of subjects), continuous intravenous GHB 
infusion at the dose of 10mg/kg/h appeared to raise 
the keratinocyte proliferative rate in the skin adjacent 
to the burn area after 21 days of treatment. This 
finding can be considered relevant when referring 
to data previously outlined in a study aiming to 
describe the basic immunohistology of burn wound 
and adjacent unburned skin: An initial peak of Ki67 
labeling was reported in both areas just after burn 
injury, followed by a marked labeling decrease 
after 20 days post‑injury (number of positive cells 
being ≤5).[12] In the present study with continuous 
GHB infusion, the evolution pattern was the opposite: 
The number of positive cells remained quite much 
high. This could be explained by the mitogen effect of 
IGF1 on keratinocytes.[13] IGF1 secretion was possibly 
stimulated by the somatotropic effect of GHB. Indeed, 
we observed that IGF1 levels were on the rise after 
21 days of continuous GHB infusion. In the present 
study, IGF1 secretion did not seem to be influenced 
by insulin: Patients of group C tented to receive lower 
intravenous insulin doses than the others.
A number of studies performed in healthy and narcoleptic 
subjects suggested that GHB represented the archetype of 
a novel class of GH secretagogue.[9,14] Administration of a 
modulator of endogenous GH secretion could be a novel 
approach in the management of burn injury. Effects of 
GH on wound healing are likely due to direct stimulation 
of cell division and protein synthesis.[15] Specific 
Table 2: Immunohistochemical data at D21
Group B n=5 Group C n=5 Group P n=4 P value
UEA-1 1 (1-1) 1 (1-0) 1 (1-1) 0.51
Mac 387 2 (0-4) 3 (1-4) 3 (2-4) 0.30
UEA-1 and Mac 387: Semi-quantitative evaluation using a 5-grade scale. Data 
are presented as median (min-max)
Figure 1: Ki67 labeling at D21 Graph shows Ki67 labeling at day 21 in each group. 
Black diamond indicates significant difference between the three groups 
(P = 0.049). Post-hoc analysis demonstrated a trend toward higher values in 
group C when compared with group B (P = 0.07)
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hormonal receptors are present on dermal fibroblasts 
and keratinocytes.[16,17] In addition, GH acts through 
stimulating IGF1 production by the liver.[18] IGF1 is 
known to be a mitogen for keratinocytes.[13]
Mechanism of GHB action is not yet fully understood. 
GHB is endogenously present in several tissues, but GHB 
binding sites are mainly located in the central nervous 
system,[19] although subtypes of receptor were recently 
identified in cardiomyocytes.[20] It is suggested that the 
mode of GHB action is driven by a central effect rather 
than a direct effect on peripheral cells (i.e., myocytes or 
keratinocytes). On one hand, the inhibitory effect of GHB 
on the dopaminergic system cannot directly explain the 
stimulation of the somatotropic axis. However, the indirect 
increase of serotonin levels after GHB administration 
could stimulate the secretion of GH through the effect 
on the dopaminergic system.[9] On the other hand, it is 
likely that GHB acts directly on the hypothalamus where 
specific binding sites have been found.[21,22] Based on more 
recent studies, it is suggested that the effects of GHB on 
GH secretion are mediated at least in part, by the effects 
of GHB on sleep.[14] It has been shown that major secretory 
pulse of GH occurs in timely association with slow wave 
sleep and particularly the first episode of a normal night.[23]
In the present study, modifications of UEA‑1 or Mac 387 
labeling in the epidermis were not observed with GHB 
treatment. Epidermis is then considered as not reactive: 
This supports the absence of keratinocyte damage due 
to GHB administration.
As it was reported that IGF1 levels were not altered 
when measured 9 hours after oral GHB ingestion,[14] we 
decided to administer GHB during several days and to 
set the evaluation time‑point at D21 in order to have time 
enough to observe any change in keratinocyte profile.
Because our study is a pilot and preliminary study, GHB 
doses were empirically determined. No data related to 
GHB administration in burn patients are available in 
the current literature. In general anesthesia conditions, 
continuous infusion is about 15 to 30 mg/kg/h. However, 
in this study, a lower infusion rate was chosen, mainly to 
avoid hypernatremia, which is a common adverse event 
in case of prolonged administration. Patients of group C 
then received a GHB dosage similar to that described 
for sedation of critically ill patients[24] In group B, the 
lower limit of regular induction doses for general 
anesthesia (i.e., 50‑100 mg/kg) was chosen: 50 mg/kg 
is a dose known to guarantee deep sedation associated 
with consistent electro‑encephalographic changes.[25] 
Results of the present study may have been influenced 
by those arbitrary choices. Higher cumulative GHB 
dose may explain improvements observed in patients 
receiving continuous infusion in contrast to daily bolus 
administration.
Current guidelines for sedation management in critically 
ill patients recommend maintaining the lightest possible 
sedation levels.[26] As nonbenzodiazepine agents are 
suggested to be preferable, GHB may be an alternative 
option given its beneficial effects. For non‑sedated patients, 
GHB could still be administered per os in the evening as in 
the treatment of narcolepsy. Further investigations should 
then consider higher dosage than in our group B as we did 
not demonstrate a sufficient effect in this group.
Finally, GHB does not seem to be the only drug that may 
stimulate keratinocyte proliferation. Similar pre‑clinical 
data were recently published with valproate acid[27] or 
zoledronate.[28] Using well‑known drugs away from their 
main indication could be in the next future an adjuvant 
treatment to promote wound healing. Depending on 
the drug, topical or systemic administration should be 
investigated in order, either to avoid adverse effects or 
to get benefit from its mode of action.
CONCLUSION
The present study is the first to consider GHB as a 
new option for promoting wound healing in human 
burn patients. This specific population experiences a 
hypermetabolic state with associated hyposomatotropism, 
leading to impaired wound healing. Even if GHB is not 
used anymore in daily practice in most of countries, it may 
be a safe adjuvant to a multimodal sedation strategy and 
it is available at low cost. Despite the limited number of 
included patients, the results of our preliminary trial are 
encouraging enough to warrant large prospective studies. 
Ideally, they should be multicentric and take advantages of 
regional and international collaborations in order to achieve 
a meaningful number of subjects. They should aim to 
confirm effectiveness of GHB to improve epithelialization, 
Figure 2: IGF1 blood concentrations at D0 and D21, over groups 
graph shows IGF1 blood concentrations at baseline (0 on x-axis) and at day 21 
(21 on x-axis) for each group. Black diamond indicates a significant increase of 
IGF1 concentrations in group C when compared with group P (P = 0.042)
International Journal of Critical Illness and Injury Science  |  Vol. 4  |  Issue 2  |  Apr-Jun 2014 113
Rousseau, et al.: Gamma‑hydroxybutyrate and keratinocytes proliferation
to determine the optimal GHB dosage regimen and finally, 
to confirm the role of GHB in a global burn care strategy.
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